MX2018007581A - Dominios variables de inmunoglobulina mejorados. - Google Patents

Dominios variables de inmunoglobulina mejorados.

Info

Publication number
MX2018007581A
MX2018007581A MX2018007581A MX2018007581A MX2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A MX 2018007581 A MX2018007581 A MX 2018007581A
Authority
MX
Mexico
Prior art keywords
amino acid
acid residue
variable domains
immunoglobulin variable
improved immunoglobulin
Prior art date
Application number
MX2018007581A
Other languages
English (en)
Inventor
Marie-Ange Buyse
Carlo Boutton
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2018007581A publication Critical patent/MX2018007581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Se describe el dominio VH, en el cual: (i) el residuo de aminoácido en la posición 112 es uno de K o Q; y/o (ii) el residuo de aminoácido en la posición en la posición 89 es T; y/o (iii) el residuo de aminoácido en la posición 89 es L y el residuo de aminoácido en la posición 110 es uno de K o Q; y (iv) en cada uno de los casos (i) a (iii), el aminoácido en la posición 11 es de manera preferente V; y en el cual el dominio VH contiene una extensión C-terminal (X)n en el cual n es uno 1 a 10, de manera preferente 1 a 5, tal como 1, 2, 3, 4, o 5 (y de manera preferente 1 o 2, tal como 1); y cada X es un residuo de aminoácido (de manera preferente de origen natural) que se elige independientemente y de manera preferente se elige independientemente del grupo que consiste de alanina (A), glicina (G), valina (V), leucina (L) o isoleucina (I) .
MX2018007581A 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados. MX2018007581A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201462014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16

Publications (1)

Publication Number Publication Date
MX2018007581A true MX2018007581A (es) 2020-11-12

Family

ID=57681120

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016014926A MX2016014926A (es) 2014-05-16 2015-05-13 Dominios variables de inmunoglobulina mejorados.
MX2018007581A MX2018007581A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.
MX2021007020A MX2021007020A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016014926A MX2016014926A (es) 2014-05-16 2015-05-13 Dominios variables de inmunoglobulina mejorados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007020A MX2021007020A (es) 2014-05-16 2016-11-14 Dominios variables de inmunoglobulina mejorados.

Country Status (12)

Country Link
US (10) US20170121399A1 (es)
JP (5) JP7325928B2 (es)
KR (5) KR20180091115A (es)
CN (3) CN109053885A (es)
CA (1) CA3175002A1 (es)
IL (5) IL299282A (es)
MX (3) MX2016014926A (es)
NZ (1) NZ726448A (es)
PH (1) PH12016502282A1 (es)
RU (2) RU2746738C2 (es)
SG (3) SG10201810124PA (es)
ZA (5) ZA201607587B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RU2746738C2 (ru) 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина
NO2768984T3 (es) * 2015-11-12 2018-06-09
WO2017080850A1 (en) * 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
TWI754622B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Ctla4結合劑
WO2017085172A2 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
WO2022206900A1 (zh) * 2021-04-01 2022-10-06 江苏先声药业有限公司 抗人血清白蛋白(hsa)的纳米抗体及其应用
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US20020155604A1 (en) 1998-02-19 2002-10-24 Jeffrey A. Ledbetter Compositions and methods for regulating lymphocyte activation
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008071447A2 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2009068630A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PT2424889E (pt) 2009-04-30 2015-11-12 Ablynx Nv Método de produção de anticorpos de domínio
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
KR101721187B1 (ko) * 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
WO2012175400A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Serum albumin binding proteins
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20130019175A1 (en) * 2011-07-14 2013-01-17 Microsoft Corporation Submenus for context based menu system
TW201321405A (zh) * 2011-08-17 2013-06-01 Glaxo Group Ltd 經修飾之蛋白質及肽
RU2603090C2 (ru) 2011-10-17 2016-11-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
DK2809681T3 (en) 2012-01-31 2019-03-11 Regeneron Pharma ANTI-ASIC1 antibodies and uses thereof
TWI641619B (zh) * 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CN104781277A (zh) 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子
RU2746738C2 (ru) 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
NO2768984T3 (es) 2015-11-12 2018-06-09
CA3005082A1 (en) 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
WO2017080850A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
KR102317574B1 (ko) 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
WO2017085172A2 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
TWI754622B (zh) 2015-11-18 2022-02-11 美商默沙東藥廠 Ctla4結合劑
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
CN114981300A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
AR120698A1 (es) * 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
EP4263602A1 (en) * 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha

Also Published As

Publication number Publication date
US11312764B2 (en) 2022-04-26
IL281755B1 (en) 2023-01-01
IL248636B (en) 2022-12-01
PH12016502282A1 (en) 2017-02-13
JP2021006563A (ja) 2021-01-21
ZA202004759B (en) 2022-08-31
KR20180091115A (ko) 2018-08-14
RU2021107470A (ru) 2021-05-17
US20220332806A1 (en) 2022-10-20
CN113717280A (zh) 2021-11-30
KR20230054503A (ko) 2023-04-24
JP7454525B2 (ja) 2024-03-22
US11319364B2 (en) 2022-05-03
CN106661100A (zh) 2017-05-10
US20210269514A1 (en) 2021-09-02
ZA202004757B (en) 2022-08-31
JP7098439B2 (ja) 2022-07-11
JP7325928B2 (ja) 2023-08-15
MX2021007020A (es) 2021-08-05
SG11201609162SA (en) 2016-12-29
KR20170002645A (ko) 2017-01-06
ZA202100742B (en) 2022-09-28
RU2746738C2 (ru) 2021-04-20
IL299282A (en) 2023-02-01
JP2021130681A (ja) 2021-09-09
US20220119512A1 (en) 2022-04-21
US20200231662A1 (en) 2020-07-23
US11220539B2 (en) 2022-01-11
US20210269515A1 (en) 2021-09-02
JP2018162297A (ja) 2018-10-18
RU2018120744A (ru) 2018-11-15
RU2016149463A (ru) 2018-06-19
IL248636A0 (en) 2017-01-31
US11485778B2 (en) 2022-11-01
RU2016149463A3 (es) 2018-07-04
IL248636B2 (en) 2023-04-01
MX2016014926A (es) 2017-05-09
JP2024041939A (ja) 2024-03-27
US11485777B2 (en) 2022-11-01
RU2018120744A3 (es) 2022-01-28
KR20230053002A (ko) 2023-04-20
US20210087261A1 (en) 2021-03-25
IL259972B (en) 2021-04-29
IL259972A (en) 2018-07-31
JP7471987B2 (ja) 2024-04-22
US20220251183A1 (en) 2022-08-11
CA3175002A1 (en) 2015-11-19
IL295534A (en) 2022-10-01
US20210261653A1 (en) 2021-08-26
US20220135657A9 (en) 2022-05-05
NZ726448A (en) 2023-02-24
US11312765B2 (en) 2022-04-26
CN109053885A (zh) 2018-12-21
ZA201607587B (en) 2022-05-25
US20220332807A1 (en) 2022-10-20
SG10201805288QA (en) 2018-07-30
SG10201810124PA (en) 2018-12-28
KR20230145503A (ko) 2023-10-17
JP2017518072A (ja) 2017-07-06
IL281755A (en) 2021-05-31
US11708404B2 (en) 2023-07-25
ZA202004758B (en) 2022-08-31
US20170121399A1 (en) 2017-05-04
IL281755B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
AU2015261536B2 (en) Improved immunoglobulin variable domains
PH12016502282A1 (en) Improved immunoglobulin variable domains
MX2020010061A (es) Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
EA201790465A1 (ru) Антитела, композиции и применение
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
MX2016008540A (es) Variantes de region fc con propiedades de union al receptor fc neonatal (fcrn).
SG10201909716RA (en) Modified j-chain
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MY182177A (en) Method for masking bitterness of composition containing collagen peptide
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
WO2014152831A3 (en) Targeting peptides and uses thereof
MX2018014490A (es) Peptido antimicrobiano modificado derivado de un dominio rico en arginina.
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
WO2015153949A3 (en) Compositions and methods for identifying ehrlichia species
PH12017550079A1 (en) Composition for improving memory, learning ability and cognition
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.
WO2014166500A3 (en) Peptides having immune suppresive domains for transfection
EP3581589A4 (en) HYBRID PEPTIDE, SET OF HYBRID PEPTIDES, COMPOSITION, USES OF THE HYBRID PEPTIDE, METHOD FOR INDUCING AN IMMUNE RESPONSE AND KITS